Articles tagged "Hyperlipidemia"

2021 American Transplant Congress
Evaluation of Safety and Efficacy of PCSK9 Inhibitors in Solid Organ Transplant Recipients: Experience at a Large Multi-organ Transplant Center
A. Ucci¹, M. Norris², J. Trofe-Clark², T. Fallah², M. Meck¹, R. Samudralwar¹, M. V. Genuardi³
¹Hospital of Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute, Hospital of Univ of Pennsylvania, Philadelphia, PA, ³Cardiovascular Medicine Div, Hospital of Univ of Pennsylvania, Philadelphia, PA
*Purpose: The aim of the study was to characterize the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in solid organ transplant…
2020 American Transplant Congress
Cardiovascular Risk Factors in Patients after Liver Transplantion
M. Adamczak¹, D. Gojowy¹, J. Stompor¹, J. Adamusik¹, G. Smiech¹, H. Karkoszka¹, R. Krol², A. Wiecek¹
¹Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland, ²Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland
*Purpose: The aim of this study was to estimate the prevalence of selected cardiovascular risk factors in patients after liver transplantation (LTx).*Methods: Medical records from…
2020 American Transplant Congress
Impact of Statin Intensity on the Development of Cardiac Allograft Vasculopathy
K. Goehring¹, W. Kuan¹, A. Sieg¹, K. L. Dawson¹, A. R. Kolodziej²
¹Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY
*Purpose: This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV)…
2019 American Transplant Congress
Multidisciplinary Practitioner Perspectives on Cardiovascular Disease Guideline Interventions in Liver Transplant Recipients
M. Kosirog¹, L. Adamski¹, A. Daud², D. Finn², D. Gregory¹, D. M. Lloyd-Jones³, J. L. Holl⁴, L. B. VanWagner⁵
¹Medicine-GI & Hepatology, Northwestern University, Chicago, IL, ²Center for Healthcare Studies, Northwestern University, Chicago, IL, ³Medicine-Cardiology and Preventive Medicine, Northwestern University, Chicago, IL, ⁴Pediatrics & Center for Healthcare Studies, Northwestern University, Chicago, IL, ⁵Medicine-GI & Hepatology and Preventive Medicine, Northwestern University, Chicago, IL
*Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in liver transplant recipients (LTRs). However, there is a lack of LT-specific CVD clinical practice…
2017 American Transplant Congress
Safety of Statin Therapy After Liver Transplantation.
M. Glynn, A. Jantz, B. Summers, R. Salgia, N. Sulejmani.
Henry Ford Hospital, Detroit, MI
Purpose: Cardiovascular disease (CVD) remains a leading cause of long-term mortality in transplant patients. A risk factor for CVD is hyperlipidemia, where the treatment is…
2016 American Transplant Congress
Higher Pre-Transplant Triglyceride Levels Are Associated with Increased Acute Cellular Rejection Risk Following Kidney Transplant.
J. Hagopian,¹ D. Brennan,² K. Lentine,³ T. Horwedel.¹
¹Barnes-Jewish Hosp, St. Louis, MO; ²Washington Univ, St. Louis, MO; ³St. Louis Univ, St. Louis, MO.
Purpose:Hyperlipidemia (HLD) has been associated with more robust immune response, possibly increasing risk for rejection. Recent articles have associated HLD with increased IL-17 production and…
2016 American Transplant Congress
Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.
A. Morales,¹ M. Singla,² H. Greenwald,¹ S. Robertazzi,¹ C. Rodigas,¹ V. Washington,¹ R. Satoskar,¹ C. Smith.¹
¹MedStar Transplant Institute, Georgetown University Hospital, Washington, DC; ²Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, MD.
The purpose of this study was to assess the effect of hepatitis C virus (HCV) eradication with sofosbuvir based regimens on glycemic and lipid control…